文献速递乳腺癌

戈沙妥珠单抗对比标准化疗治疗转移性三阴性乳腺癌III期ASCENT试验中的健康相关生活质量

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
PubMed 文献 · Eur J Cancer · 2022-10-18

基于开放标签III期ASCENT试验,236例接受戈沙妥珠单抗(SG)、183例接受医生选择治疗(TPC)的难治/复发转移性三阴性乳腺癌患者,采用EORTC QLQ-C30评估健康相关生活质量(HRQoL)。SG在整体健康状况/生活质量、躯体功能、疲乏和疼痛方面从基线的变化优于TPC,但恶心/呕吐和腹泻劣于TPC;SG在躯体功能、角色功能、疲乏和疼痛方面至首次临床意义恶化的中位时间均长于TPC。

要点

  • SG在整体健康状况/生活质量、躯体功能、疲乏和疼痛方面从基线的变化优于TPC。
  • SG在恶心/呕吐和腹泻方面从基线的变化劣于TPC,其余QLQ-C30领域非劣于TPC。
  • SG至躯体功能、角色功能、疲乏和疼痛首次临床意义恶化的中位时间均长于TPC。

核心结论

  • SG总体上与HRQoL评分更大改善和恶化延迟相关,支持SG作为转移性三阴性乳腺癌治疗的良好特征。

研究设计与样本

  • 基于开放标签III期ASCENT试验(NCT02574455)的分析。
  • 纳入既往接受≥2线全身治疗(转移阶段≥1线)的难治/复发转移性三阴性乳腺癌成人患者,按1:1随机分配至SG组或医生选择治疗(TPC)组。
  • TPC包括卡培他滨、艾立布林、长春瑞滨或吉西他滨。
  • HRQoL于每个治疗周期第1天采用EORTC QLQ-C30评估,采用线性混合效应模型分析自基线变化。
  • 采用分层Cox回归评估至首次临床意义HRQoL变化的时间。

主要发现

  • 分析人群包括SG组236例和TPC组183例。
  • 整体健康状况/生活质量、躯体功能、疲乏和疼痛从基线的变化SG优于TPC。
  • 恶心/呕吐和腹泻从基线的变化SG劣于TPC,其他QLQ-C30领域SG非劣于TPC。
  • 至首次临床意义恶化的中位时间SG均长于TPC:躯体功能22.1周 vs 12.1周(P < 0.001),角色功能11.4周 vs 7.1周(P < 0.001),疲乏7.7周 vs 6.0周(P < 0.05),疼痛21.6周 vs 9.9周(P < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The antibody-drug conjugate sacituzumab govitecan (SG) prolongs progression-free survival and overall survival in patients with refractory/relapsed metastatic triple-negative breast cancer (mTNBC). Here, we investigated its effect on health-related quality of life (HRQoL). METHODS: This analysis was based on the open-label phase III ASCENT trial (NCT02574455). Adults with refractory/relapsed mTNBC who had received ≥2 prior systemic therapies (≥1 in the metastatic setting) were randomised 1:1 to SG or treatment of physician's choice (TPC; capecitabine, eribulin, vinorelbine, or gemcitabine). HRQoL was assessed on day 1 of each treatment cycle using the EORTC QLQ-C30. Score changes from baseline were analysed using linear mixed-effect models for repeated measures. Stratified Cox regressions evaluated time to first clinically meaningful change of HRQoL. RESULTS: The analysis population comprised 236 patients randomised to SG and 183 to TPC. For global health status (GHS)/QoL, physical functioning, fatigue, and pain, changes from baseline were superior for SG versus TPC. Compared with TPC, SG was inferior regarding changes from baseline for nausea/vomiting and diarrhoea but non-inferior for other QLQ-C30 domains. Median time to first clinically meaningful worsening was longer for SG than for TPC for physical functioning (22.1 versus 12.1 weeks, P < 0.001), role functioning (11.4 versus 7.1 weeks, P < 0.001), fatigue (7.7 versus 6.0 weeks, P < 0.05), and pain (21.6 versus 9.9 weeks, P < 0.001). CONCLUSIONS: SG was generally associated with greater improvements and delayed worsening of HRQoL scores compared with TPC. This supports the favourable profile of SG as an mTNBC treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Loibl S, Loirat D, Tolaney SM, et al. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. Eur J Cancer. 2022. PMID: 36379186. doi:10.1016/j.ejca.2022.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。